Ozagrel: Difference between revisions
CSV import |
CSV import |
||
| Line 23: | Line 23: | ||
{{stub}} | {{stub}} | ||
<gallery> | |||
File:Ozagrel.svg|Ozagrel | |||
File:Ozagrel_synthesis.svg|Ozagrel synthesis | |||
</gallery> | |||
Latest revision as of 01:51, 17 February 2025
Ozagrel is a thromboxane A2 (TXA2) synthase inhibitor. It is used in the treatment of cerebral infarction and its sequelae. Ozagrel works by inhibiting the synthesis of thromboxane, which is a substance that causes blood clot formation and blood vessel constriction.
Mechanism of Action[edit]
Ozagrel inhibits the enzyme thromboxane A2 synthase, which is responsible for the production of thromboxane. Thromboxane is a potent vasoconstrictor and a potent inducer of platelet aggregation. By inhibiting the production of thromboxane, Ozagrel reduces the risk of blood clot formation and blood vessel constriction, which can lead to cerebral infarction.
Uses[edit]
Ozagrel is used in the treatment of cerebral infarction and its sequelae. Cerebral infarction is a type of stroke caused by a blockage in the blood vessels supplying blood to the brain. The sequelae of cerebral infarction can include paralysis, speech impairment, and cognitive impairment.
Side Effects[edit]
The most common side effects of Ozagrel include nausea, vomiting, abdominal pain, and diarrhea. Less common side effects can include dizziness, headache, rash, and itching.
Contraindications[edit]
Ozagrel is contraindicated in patients with a history of hypersensitivity to Ozagrel or any of its components. It is also contraindicated in patients with active gastrointestinal bleeding or a history of asthma.
